Ozempic shown to reduce drinking in first trial in alcohol-use disorder
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
Futurism1d
Doctors Have One Weird Trick to Tell When Their Colleagues Are On Ozempic
Doctors have begun noticing a trend: they all seem to get full before finishing dinner, and it's likely thanks to drugs like ...
BioSpace1d
Explainer: The Thriving Shadow Market of GLP-1s for Weight Loss
Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...
WDRB1d
The 2 sides of Ozempic — weight loss success stories and health nightmares in Kentucky
The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...
Rolling Out2d
Illegal weight loss drug sales flourish on social media
Discover why people risk buying Ozempic and similar weight loss medications through social media, the devastating consequences, and legitimate ways to treatment ...
The Physicians Really Are Healing Themselves, With Ozempic
There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...
stockhead2d
Ozempic’s PBS push could shake up ASX food stocks, and here’s how
Big pharma’s pushing for PBS funding, and it’s kickstarting a shift to healthier snacks, smaller portions, and more ...
Rolling Out3d
The weight loss drug dilemma no one wants to talk about
GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...
Eli Lilly and Company (LLY): Among Ken Fisher’s Top High Growth Stock Picks
Ken Fisher is the founder and executive chairman of Fisher Asset Management, a renowned investment and financial analysis ...
Is the promise of more affordable weight loss drugs too good to be true? Compounded semaglutide, explained.
Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.
BioSpace5d
After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’
As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...
Eli Lilly Q4: Don't Miss Out On 2025 Gains, There's Limited Space Left
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...